Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial
Publication date: Available online 30 June 2018Source: PM&RAuthor(s): Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis, Joao SiffertAbstractBackgroundDextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.ObjectiveTo report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS).DesignOpen-label trial evaluating twice daily DM/Q over 90 daysStudy participantsAdults (n=113) with a clinical diagnosis of PBA secondary to stroke; stable psychiatric medications were allowed.MethodsPRISM II was an open-label, 12-week trial enrolling adults with PBA secondary to dementia, stroke (reported here), or TBI. All study participants received DM/Q 20/10 mg twice daily. Study visits occurred at baseline and at day 30 and day 90.Setting150 US centers.Main Outcome MeasurementsPrimary efficacy measure was change from baseline to day 90 in Center for Neurologic Study-Lability Scale (CNS-LS) scores. Secondary outcomes included PBA episodes (estimated over 7 days), Clinical and Patient/Caregiver Global Impression of Change (CGI-C and PGI-C), Quality of Life-Visual Analog Scale (QOL-VAS), SIS, Patient Health Questionnaire (PHQ-9), and Mini-Mental State Examination (MMS...
Non-inherited forms of dementia likely develop because of spontaneous " spelling mistakes " in DNA that arise as cells divide and reproduce, according to a study.
We report for the first time an association between altered BA profile, genetic variants implicated in AD, and cognitive changes in disease using a large multicenter study. These findings warrant further investigation of gut dysbiosis and possible role of gut-liver-brain axis in the pathogenesis of AD.
ConclusionsIn the real-life scenario ~54% of patients with acromegaly resistant to first-generation SSA, may normalize IGF-1 with pasireotide; however, 63% experienced glucose control deterioration.
Neuroscientists at the University of Pennsylvania found teenage who cut down on sleep were more likely to develop dangerous build-ups in their brain that paved the way to dementia.
This article is part of a series of opinion pieces to mark World Food Day October 16 José Graziano da Silva is Director-General of the Food and Agriculture Organization of the United NationsThe post Zero Hunger: our actions today are our future tomorrow appeared first on Inter Press Service.
Buffalo General Medical Center has received state approvals to add 4-D imaging equipment adjacent to its emergency department, a move it says will “revolutionize” stroke treatment. The hospital filed plans this summer to invest $2.5 million in a 4-Dimensional Computed Tomography system from Canon Medical USA, creating a cardiac catheterization lab suite within Buff Gen’s Gates Vascular Institute emergency department. The state Departme nt of Health approved the project Oct. 10. The equipment…
Conditions: Multiple Sclerosis; Spasticity, Muscle; Balance; Distorted Intervention: Other: cervical mobilisation Sponsor: Hacettepe University Not yet recruiting
Condition: Stroke Intervention: Behavioral: Cardiac Rehabilitation Sponsors: University of South Carolina; Novant Health Heart and Vascular Institute; American Physical Therapy Association Recruiting
Researchers from the University of Cambridge found that mutations that lead to the disease can occur spontaneously while the brain is developing in the uterus rather than being inherited.
The findings of a new study suggest that some antidepressants may block the growth of toxic plaques in the brain, thus helping to treat dementia.